REPLIGEN CORP Income Taxes Paid
REPLIGEN CORP (RGEN) reported Income Taxes Paid of $937.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2018-05-08
- REPLIGEN CORP income taxes paid for the quarter ending 2018-03-31 was $937.00K, a 20.66% decline year-over-year.
- REPLIGEN CORP income taxes paid for the quarter ending 2017-12-31 was $466.00K, a 57.83% decline year-over-year.
- REPLIGEN CORP income taxes paid for the quarter ending 2017-09-30 was $1.41M, a 54.91% increase year-over-year.
- REPLIGEN CORP income taxes paid for the quarter ending 2017-06-30 was $969.00K, a 2.87% increase year-over-year.
- REPLIGEN CORP income taxes paid for fiscal 2017 was $4.02M, a 0.70% increase from fiscal 2016.
- REPLIGEN CORP income taxes paid for fiscal 2016 was $3.99M, a 19.30% decline from fiscal 2015.
- REPLIGEN CORP income taxes paid for fiscal 2015 was $4.95M, a 94.27% increase from fiscal 2014.
- REPLIGEN CORP income taxes paid for fiscal 2014 was $2.55M, a 101.50% increase from fiscal 2013.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month |
|---|---|---|---|---|
| 2018-03-31 | $937.00K 10-Q · filed 2018-05-08 | $1.40M derived: sum of 2 quarters · filed 2018-05-08 | $2.81M derived: sum of 3 quarters · filed 2018-05-08 | $3.78M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | $466.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $1.87M derived: sum of 2 quarters · filed 2018-02-22 | $2.84M derived: sum of 3 quarters · filed 2018-02-22 | $4.02M 10-K · filed 2018-02-22 |
| 2017-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $2.37M derived: sum of 2 quarters · filed 2017-11-09 | $3.56M 10-Q · filed 2017-11-09 | $4.66M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | $969.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $2.15M 10-Q · filed 2017-08-03 | $3.25M derived: sum of 3 quarters · filed 2018-05-08 | $4.16M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | $1.18M 10-Q · filed 2018-05-08 | $2.29M derived: sum of 2 quarters · filed 2018-05-08 | $3.19M derived: sum of 3 quarters · filed 2018-05-08 | $4.13M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $2.01M derived: sum of 2 quarters · filed 2018-02-22 | $2.95M derived: sum of 3 quarters · filed 2018-02-22 | $3.99M 10-K · filed 2018-02-22 |
| 2016-09-30 | $907.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.85M derived: sum of 2 quarters · filed 2017-11-09 | $2.89M 10-Q · filed 2017-11-09 | $5.17M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-06-30 | $942.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $1.98M 10-Q · filed 2017-08-03 | $4.26M derived: sum of 3 quarters · filed 2018-02-22 | $5.30M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-03-31 | $1.04M 10-Q · filed 2017-05-04 | $3.32M derived: sum of 2 quarters · filed 2018-02-22 | $4.36M derived: sum of 3 quarters · filed 2018-02-22 | $4.89M derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $3.32M derived: sum of 2 quarters · filed 2018-02-22 | $3.85M derived: sum of 3 quarters · filed 2018-02-22 | $4.95M 10-K · filed 2018-02-22 |
| 2015-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.57M derived: sum of 2 quarters · filed 2016-11-03 | $2.67M 10-Q · filed 2016-11-03 | $4.55M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.63M 10-Q · filed 2016-08-04 | $3.50M derived: sum of 3 quarters · filed 2017-02-23 | $3.51M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $1.10M 10-Q · filed 2016-05-05 | $2.98M derived: sum of 2 quarters · filed 2017-02-23 | $2.98M derived: sum of 3 quarters · filed 2017-02-23 | $3.18M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $1.88M derived: sum of 2 quarters · filed 2017-02-23 | $2.08M derived: sum of 3 quarters · filed 2017-02-23 | $2.55M 10-K · filed 2017-02-23 |
| 2014-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $205.00K derived: sum of 2 quarters · filed 2015-11-05 | $671.00K 10-Q · filed 2015-11-05 | $739.00K derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $668.00K 10-Q · filed 2015-08-06 | $736.00K derived: sum of 3 quarters · filed 2016-02-25 | $1.16M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $466.00K 10-Q · filed 2015-05-08 | $534.00K derived: sum of 2 quarters · filed 2016-02-25 | $959.00K derived: sum of 3 quarters · filed 2016-02-25 | $1.07M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $493.00K derived: sum of 2 quarters · filed 2016-02-25 | $605.00K derived: sum of 3 quarters · filed 2016-02-25 | $1.26M 10-K · filed 2016-02-25 |
| 2013-09-30 | $425.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $537.00K derived: sum of 2 quarters · filed 2014-11-07 | $1.20M 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $771.00K 10-Q · filed 2014-08-11 | ||
| 2013-03-31 | $659.00K 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $140.00K 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |